NCT00731172View on ClinicalTrials.gov

A Double Blind Placebo Control Study to Assess the Safety,Tolerability and Efficacy of Copaxone in Crohn's Disease

PHASE2UnknownINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2011

Conditions
Crohns Disease
Interventions
DRUG

glatiramer acetate

20 mg daily subcutaneous injection through week 12

DRUG

placebo

subcutaneous daiky injection through week 12

Trial Locations (2)

64239

RECRUITING

Tel Aviv Sourasky medical center, Tel Aviv

76100

NOT_YET_RECRUITING

Weizmann Institute of Science, Rehovot

Sponsors

Collaborators (1)

Medtronic - MITG
All Listed Sponsors
collaborator

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

collaborator

Medtronic - MITG

INDUSTRY

lead

Tel-Aviv Sourasky Medical Center

OTHER_GOV